CClinicalTrials.gg
Status unknownNCT03306940BTATHSUpdated Oct 12, 2017

Botulinum Toxin A in the Treatment of Hemifacial Spasm

An interventional study of Botulinum Toxin Type A in Hemifacial Spasm, sponsored by Tongji University. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-10-12.

Sponsored by Tongji University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Hemifacial spasm patients who received botulinum toxin A injection were divided into two groups. Group A received unilateral injection while group B received bilateral injection. Patients completed follow-up A researcher record facial videos and analyzed facial symmetry and completed 3 scales.

Read the detailed description

Hemifacial spasm patients who received botulinum toxin A injection were divided into two groups.Patients of unilateral group were injected to the affected side and the dose of botulinum toxin A was 2.5-3.75 units/per site. Patients of bilateral group were injected to the affected side with dose of 2.5-3.75 units/per site and the normal side was injected with dose of 1.25 units/per site.

3 scales for measurement were used.

02

Conditions studied

  • Hemifacial Spasm

Keywords

  • botulinum toxin A
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • clinical diagnosis of hemifacial spasm
  • Scott grading III to IV
  • hemifacial spasm duration of half or more years
  • last botulinum toxin A application at least 3 months before the start of the study

Exclusion criteria

Exclusion Criteria:

  • history of facial trauma, congenital facial asymmetry, facial nerve microsurgical decompression
  • bilateral hemifacial spasm
  • allergies to botulinum toxin A or to any component of the drug
  • previous treatment with botulinum toxin A fewer than 3 months
  • the use of drugs that could interfere with neuromuscular transmission or spasm
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Placebo comparator
    unilateral injection group

    Patients of unilateral group were injected botulinum toxin type A to the affected hemiface.

    Drug: Botulinum Toxin Type A

  • Experimental
    bilateral injection group

    Patients of bilateral group were injected botulinum toxin type A to the affected hemiface and normal hemiface. The intervention of the bilateral group was that the normal side was injected.

    Drug: Botulinum Toxin Type A

Interventions

  • DrugBotulinum Toxin Type A

    patients were injected to the normal side with dose of 1.25 units/per site

    Also known as: Chinese botulinum toxin type A

05

What researchers measure

Primary outcomes

  1. Sunnybrook Facial Grading System

    Sunnybrook Facial Grading System consists of resting symmetry, symmetry of voluntary movement and synkinesis. Total score = Symmetry of voluntary movement score - Resting symmetry score - Synkinesis score

    Time frame: up to 6 months

Secondary outcomes

  1. Symmetry Scale for Hemifacial Spasm

    Symmetry Scale for Hemifacial Spasm consists of resting symmetry and symmetry of voluntary movement. Total score =Resting symmetry score + Symmetry of voluntary movement score

    Time frame: up to 6 months

  2. Facial Clinimetric Evaluation Scale

    Facial Clinimetric Evaluation Scale consists of six parts:facial movement,facial comfort,oral function,eye comfort,lacrimal control and social function. Total score = facial movement + facial comfort + oral function + eye comfort + lacrimal control + social function.

    Time frame: up to 6 months

  3. The effective duration of botulinum toxin A

    degree of amelioration in spasm and the effective duration of botulinum toxin A

    Time frame: up to 6 months

  4. Adverse events

    Adverse events, including stiff face, difficulty drinking and eating, difficulty controlling parotid and so on.The onset and duration of adverse events.Whether to take intervention to ameliorate adverse events and the efficacy of the intervention

    Time frame: up to 6 months

06

Study locations

1 of 1 sites recruiting
  • Shanghai Tongji Hospital
    Shanghai, Shanghai 200065, China
    Recruiting
07

References and documents

Publications

  • Tan NC, Chan LL, Tan EK. Hemifacial spasm and involuntary facial movements. QJM. 2002 Aug;95(8):493-500. doi: 10.1093/qjmed/95.8.493. PubMed 12145388 ↗
  • Fujimura T, Hotta M. The preliminary study of the relationship between facial movements and wrinkle formation. Skin Res Technol. 2012 May;18(2):219-24. doi: 10.1111/j.1600-0846.2011.00557.x. Epub 2011 Aug 25. PubMed 22092807 ↗
  • Isse NG. Endoscopic facial rejuvenation: endoforehead, the functional lift. Case reports. Aesthetic Plast Surg. 1994 Winter;18(1):21-9. doi: 10.1007/BF00444243. PubMed 8122572 ↗
  • Xiao L, Pan Y, Zhang X, Hu Y, Cai L, Nie Z, Pan L, Li B, He Y, Jin L. Facial asymmetry in patients with hemifacial spasm before and after botulinum toxin A treatment. Neurol Sci. 2016 Nov;37(11):1807-1813. doi: 10.1007/s10072-016-2670-2. Epub 2016 Jul 18. PubMed 27431279 ↗
  • Kim J. Contralateral botulinum toxin injection to improve facial asymmetry after acute facial paralysis. Otol Neurotol. 2013 Feb;34(2):319-24. doi: 10.1097/mao.0b013e31827c9f58. PubMed 23444480 ↗
  • Borodic GE, Cheney M, McKenna M. Contralateral injections of botulinum A toxin for the treatment of hemifacial spasm to achieve increased facial symmetry. Plast Reconstr Surg. 1992 Dec;90(6):972-7; discussion 978-9. PubMed 1448532 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03306940
Lead sponsor
Tongji University
Responsible party
Lingjing Jin (professor, Tongji University) — Principal investigator
First posted
Oct 11, 2017
Start date
Oct 2, 2017
Primary completion
Jul 31, 2018 (estimated)
Completion
Aug 31, 2018 (estimated)
Last update
Oct 12, 2017

Study contacts

Lingjing Jin, PhD
Contact
1164427300@qq.com
+86 02166111310
Libin Xiao, MBA
Contact
xiaolibinjiayou@163.com
+86 13916266214
Lingjing Jin, PhD
principal investigator · Shanghai Tongji Hospital, Tongji University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion